- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07951320
Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors (RESET-PsO)
Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Trial
This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.
Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.
Both groups receive recaticimab after the Week 16 assessments through Week 32, with safety follow-up at Week 36.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
After screening of up to 4 weeks, participants are randomized 1:1 to recaticimab or matching placebo while continuing their established IL-17A inhibitor regimen.
Recaticimab 150 mg or matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After the Week 16 efficacy assessments, both groups receive recaticimab 150 mg at Weeks 16, 20, 24, 28, and 32. Safety follow-up is at Week 36, without study-drug administration. Post-Week 16 comparisons are exploratory.
A prespecified interim analysis may increase total enrollment from 100 to a maximum of 150 participants.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yi Xiao
- Numéro de téléphone: +86 137 8719 1233
- E-mail: xiaoyixy@csu.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Yehong Kuang
- Numéro de téléphone: +86 13574171102
- E-mail: yh_927@126.com
Lieux d'étude
-
-
-
Shanghai, Chine
- Shanghai Skin Disease Hospital
-
-
Hunan
-
Changde, Hunan, Chine
- Changde First People's Hospital
-
Changsha, Hunan, Chine
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, Chine
- Xiangya Hospital, Central South University
-
Changsha, Hunan, Chine
- The Third Xiangya Hospital of Central South University
-
-
Liaoning
-
Dalian, Liaoning, Chine
- Dalian Dermatology Hospital
-
Shenyang, Liaoning, Chine
- Central Hospital Affiliated to Shenyang Medical College
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Participants must meet all of the following criteria:
-
Understand the study requirements and procedures, voluntarily provide written informed consent, and be willing and able to comply with the protocol.
-
Be male or female and aged 18 to 75 years, inclusive.
-
Have a clinical diagnosis of plaque psoriasis that was moderate to severe before starting the current interleukin-17A (IL-17A) inhibitor.
-
Meet the following prior-treatment and prior-response requirements for secondary treatment failure:
Moderate-to-severe plaque psoriasis before starting the current IL-17A inhibitor must be supported by contemporaneous medical records. The investigator must verify the severity classification and its basis with reference to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 edition).
The total duration of treatment with the current IL-17A inhibitor before enrollment must be at least 16 weeks. The actual cumulative dose received must be at least 80% of the cumulative dose calculated according to the product-label-recommended regimen over the same treatment period.
A prior good clinical response during treatment with this drug must be supported by verifiable medical records and meet at least one of the following four conditions:
- Recorded Psoriasis Area and Severity Index (PASI) scores demonstrate a reduction of at least 90% from the PASI score before starting that IL-17A inhibitor, corresponding to a PASI90 response.
- Contemporaneous medical records document a static Physician's Global Assessment (sPGA) or Investigator's Global Assessment (IGA) score of 0 or 1, with these categories corresponding to clear or almost clear on the scale used.
- Contemporaneous physician records explicitly document clear or almost clear skin lesions.
- Contemporaneous medical records document that the percentage of body surface area affected by psoriasis (BSA) decreased to 1% or less during treatment with the same current IL-17A inhibitor.
The requirement for documented moderate-to-severe disease before treatment applies to all four pathways. Available pretreatment PASI, BSA, sPGA/IGA, Dermatology Life Quality Index (DLQI), and clinical severity assessments must be recorded; all four scales are not required. The PASI90 pathway requires PASI values from both before and during treatment with that drug. Each other pathway requires the relevant on-treatment record and evidence of moderate-to-severe disease before treatment. The investigator must verify the drug, dates, overall skin involvement, and source of evidence. Patient recall alone or a history of biologic use alone is insufficient. Missing historical scores must not be reconstructed.
-
After achieving at least one of the good-response criteria above, have subsequent worsening while continuing the same IL-17A inhibitor, with PASI ≥3 and sPGA ≥2 at both screening and the Week 0 baseline visit, and an investigator judgment that a change in treatment strategy is needed. The investigator must review the prior response, worsening, and treatment records to confirm their temporal sequence and determine that the current worsening is not primarily attributable to treatment interruption or substantial nonadherence.
-
Have dyslipidemia with fasting low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L and <4.9 mmol/L, without atherosclerotic cardiovascular disease (ASCVD).
-
Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. Male and female participants of reproductive potential must agree to use highly effective contraception throughout the study and for 30 days after the last dose of study drug. Participants must also comply with the contraception requirements for their background IL-17A inhibitor. Any longer contraception periods specified in the applicable prescribing information or investigator's brochure must also be observed.
-
Be willing to complete the required protocol examinations and assessments. Participation in optional assessments is voluntary, and declining them does not affect eligibility for the main study.
Exclusion Criteria:
Participants meeting any of the following criteria are excluded:
- A diagnosis of non-plaque psoriasis at screening or baseline, including guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis.
- Severe hypersensitivity to an active ingredient or any excipient of the study drugs.
- Concomitant malignancy.
- Any previous or current PCSK9-targeted therapy, including PCSK9 monoclonal antibodies or PCSK9-targeting small interfering RNA (siRNA) drugs, such as inclisiran.
- Current treatment at screening with other lipid-lowering drugs, such as statins or ezetimibe. Clinically necessary lipid-lowering treatment must not be discontinued to meet study eligibility criteria.
- Treatment with a biologic targeting a pathway other than IL-17A, or a small-molecule targeted drug, within 4 weeks before screening.
- Clinically significant active disease, such as active tuberculosis or active hepatitis.
- Participation in another clinical trial with use of a trial-related drug within 3 months before screening.
- Pregnancy, breastfeeding, or planned pregnancy during the study; or unwillingness of a male or female participant to use contraception.
- Major surgery within 3 months before screening or planned major surgery during the study.
- Renal impairment with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² during screening.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), or total bilirubin >2 times ULN.
- New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction <30%.
- Previously or currently diagnosed ASCVD, including coronary heart disease, ischemic stroke, or atherosclerotic peripheral artery disease; or another type of stroke within 3 months before randomization.
- A need to promptly initiate, continue, or intensify lipid-lowering drug therapy, based on an assessment of overall ASCVD risk and lipid-lowering treatment needs according to the Chinese Guidelines for Lipid Management (2023), such that treatment should not be delayed during the 16-week controlled treatment period.
- Any other condition that, in the investigator's judgment, makes participation inappropriate.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Recaticimab Plus Background IL-17A Inhibitor
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants receive recaticimab 150 mg subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit. |
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments. |
|
Comparateur placebo: Placebo Plus Background IL-17A Inhibitor
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants switch to recaticimab 150 mg administered subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit. |
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments. Matching placebo is administered subcutaneously to participants assigned to the placebo comparator arm at Weeks 0, 4, 8, and 12 during the double-blind, placebo-controlled period. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of participants achieving PASI75 at Week 16
Délai: Week 16
|
PASI75 is defined as a ≥75% reduction in the Psoriasis Area and Severity Index (PASI) score from the Week 0 randomization baseline. |
Week 16
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean percentage improvement from baseline in sPGA × BSA at Week 16
Délai: Baseline (Week 0) and Week 16
|
sPGA × BSA is the sPGA score multiplied by affected BSA (%). Mean individual percentage improvement is calculated as 100 × (Week 0 value - Week 16 value) / Week 0 value. |
Baseline (Week 0) and Week 16
|
|
Mean change from baseline in PASI score
Délai: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Mean change from the Week 0 PASI score. PASI ranges from 0 to 72; higher scores indicate more severe disease. |
Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Mean percentage improvement from baseline in PASI score
Délai: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Mean of individual percentage improvements in PASI: 100 × (Week 0 score - post-baseline score) / Week 0 score. Higher values indicate greater improvement. |
Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants achieving PASI50
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with at least a 50% reduction in PASI from the Week 0 randomization baseline. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants achieving PASI90
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with at least a 90% reduction in PASI from the Week 0 randomization baseline. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants achieving PASI100
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with a 100% reduction in PASI from the Week 0 randomization baseline. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants with sPGA 0 or 1
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). The scale ranges from 0 to 4. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Change from baseline in skin itch Numeric Rating Scale score
Délai: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Change from Week 0 in skin itch Numeric Rating Scale (NRS) score, ranging from 0 (no itch) to 10 (worst imaginable itch). |
Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Change from baseline in Dermatology Life Quality Index score
Délai: Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
|
Change from the last valid pre-dose Dermatology Life Quality Index (DLQI) score. Scores range from 0 to 30; higher scores indicate worse quality of life. |
Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
|
|
Percentage change from baseline in low-density lipoprotein cholesterol
Délai: Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
|
Percentage change in LDL-C: 100 × (post-baseline - baseline) / baseline. Baseline is the last valid pre-dose measurement. |
Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
|
|
Participants with treatment-emergent adverse events
Délai: From the first study dose through Week 36
|
Number and percentage of participants with adverse events occurring after the first study dose through the final safety follow-up visit. |
From the first study dose through Week 36
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, Honarpour N, Keech AC, Sever PS, Sabatine MS, Giugliano RP. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025 May 20;151(20):1467-1476. doi: 10.1161/CIRCULATIONAHA.124.072756. Epub 2025 Apr 21.
- Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025 Jan;92(1):92-99. doi: 10.1016/j.jaad.2024.09.031. Epub 2024 Sep 26.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MA-DER-IV-050
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .